Frank Karbe
Patrimonio netto: 647 325 $ in data 31/05/2026
Patrimonio netto: 647 325 $ in data 31/05/2026
Mr. Frank L.
Karbe is a Chief Financial & Accounting Officer at Cidara Therapeutics, Inc. and an Independent Director at Phathom Pharmaceuticals, Inc. He is on the Board of Directors at Phathom Pharmaceuticals, Inc. and Navigen, Inc. Mr. Karbe was previously employed as a President, CEO, Secretary & Treasurer by Better Therapeutics, Inc., an Independent Director by Aduro BioTech, Inc., a President, CFO & Chief Accounting Officer by Myovant Sciences Ltd., a President by Myovant Sciences, Inc., a President by The Color Run LLC, an Independent Director by Arbutus Biopharma Corp., a Chief Financial Officer & Executive Vice President by Exelixis, Inc., and a Vice President-Healthcare Group by Goldman Sachs & Co. He also served on the board at Kolltan Pharmaceuticals, Inc.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 19/05/2026 | 67.500 ( 0,08% ) | 647 325 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 25/04/2022 |
| CIDARA THERAPEUTICS | Direttore Finanziario/CFO | 24/02/2025 |
Navigen, Inc.
Navigen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development company | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| BETTER THERAPEUTICS, INC. | Amministratore Delegato | 14/03/2024 |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for women''s health and prostate cancer | Presidente | 12/08/2021 |
| MYOVANT SCIENCES LTD. | Direttore Finanziario/CFO | 12/08/2021 |
| CHINOOK THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 05/10/2020 |
| ARBUTUS BIOPHARMA CORPORATION | Direttore/Membro del Consiglio | 01/01/2018 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 12 |
|---|---|
Exelixis, Inc.
Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Arbutus Biopharma Corp.
Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Aduro BioTech, Inc.
Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company, which focuses on the development of technology platforms for cancer | Health Technology |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Health Technology |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Navigen, Inc.
Navigen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development company | Health Technology |
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Engages in the discovery, development, and commercialization of novel anti-infectives | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for women''s health and prostate cancer | Health Technology |
The Color Run LLC
The Color Run LLC Movies/EntertainmentConsumer Services Operates as event management company | Consumer Services |
Myovant Sciences Ltd.
Myovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides women's health and prostate cancer solutions | Health Technology |
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel treatments for gastrointestinal diseases and disorders | Health Technology |
Better Therapeutics, Inc.
Better Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops prescription digital therapeutics for the treatment of cardiovascular and metabolic diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale